Navigation Links
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO

FREDERICK, Md., Sept. 30 /PRNewswire/ -- Vaccinogen, Inc. has appointed veteran biotechnology executive Michael L. Kranda as President and Chief Executive Officer to guide it through its next stage of growth.

"The timing couldn't be better – as the company proceeds to finance and launch our pivotal Phase III clinical trial," said Michael G. Hanna, Jr., Ph.D., Vaccinogen's Founder & Chairman and inventor of the company's unique cancer-fighting vaccine OncoVAX®.

Co-founder and COO Andrew L. Tussing said Mr. Kranda was the clear choice to head the break-through biopharmaceutical company.  "He has the vision and experience to lead us through this important phase in our growth," Mr. Tussing said.

"I'm excited about OncoVAX®'s potential to save lives and Vaccinogen's role as a pioneer in using autologous vaccines to combat cancer," said Mr. Kranda.  "I look forward to building on the OncoVAX® technology to create an important and leading company in the cancer vaccine arena."

Literally Turning Cancer on Itself™, Vaccinogen works to harness the body's immune system to prevent the recurrence of cancer in patients recovering from the disease.

Mr. Kranda brings to Vaccinogen more than two decades of experience developing biotechnology platforms, products and companies. He sits on the board of directors of several companies including PTC Therapeutics.

Previously, Mr. Kranda served as the CEO, President and Director of Anesiva. Prior to joining Anesiva, Mr. Kranda was Managing Director of Vulcan Capital, Paul Allen's investment arm, where he led the life science venture investments team.  Mr. Kranda also served as CEO of Oxford GlycoSciences, and led their listings on the LSE and NASDAQ exchanges and prior to that was President and COO of Immunex (now Amgen).

Mr. Kranda holds a BA and an MBA from the University of Washington School of Business.

About OncoVAX®OncoVAX® transforms the body's immune response to prevent the return of the disease after surgery. As published in the journal Human Vaccines, Stage II OncoVAX® patients achieve "a 57.1% relative risk reduction in the recurrence of colon cancer" vs. the control patients in a previous clinical trial.

About VaccinogenVaccinogen develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer in various stages of clinical development.

www.vaccinogeninc.comContact:Andrew L. TussingVaccinogenatussing@vaccinogeninc.com301-668-8400

SOURCE Vaccinogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RF Technologies® Names Mark Harwood New President
2. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
3. and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Domain Development Conference
4. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
5. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
8. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
11. Thomson Reuters Names the Worlds Hottest Researchers
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):